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Comments on ‘‘Short-term reasons
for withdrawal and adverse events
associated with apremilast therapy
for psoriasis in real-world practice
compared with in clinical trials: A
multicenter retrospective study’’To the Editor: The effect of apremilast in the
treatment of psoriatic arthritis (PsA) has been
assessed in the Psoriatic Arthritis Long-term
Assessment of Clinical Efficacy (PALACE) phase III
clinical trial program,1-3 but observational data are
still lacking. We read with great interest the article
by Ighani et al,4 who compared the safety profile
of apremilast observed in a real-life cohort of
psoriasis patients with that in the main randomized
controlled trials. They found worse apremilast
tolerability in real-life patients, with a significantly
greater number of withdrawals because of adverse
events (AEs).Table I. Baseline characteristics and safety profile of apre
RAPPER cohort
Indicator
RAPPER
(N = 131)
PALACE
(N = 168
Baseline characteristics
Female, n (%) 83 (63.3) 92 (54
Mean age, y (SD) 57.5 (12) 51.4 (11
Mean duration of PsA, y (SD) 10.8 (12.4) 8.1 (8.1
Mean weight, kg (SD) 73.3 (18.7) 87.1 (19
Mean body mass index, kg/m2 (SD) 27.8 (16.3) 30.6 (5.9
Prior use of biologics, n (%) 62 (47.7) 41 (24
Concomitant csDMARD use, n (%) 47 (35.9) 106 (63
Overall AEs
Diarrhea 19 (14.5) 32 (19
Headache 12 (9.1) 18 (10
Nausea/vomiting 10 (7.6) 31 (18
Depression 1 (0.7)
UC relapse 1 (0.7)
Weight loss 2 (1.4)
Upper respiratory tract infection 6 (4.5) 7 (4.2
Rash 1 (0.7)
Abdominal pain 7 (5.3)
Herpes zoster infection 1 (0.7)
AEs leading to discontinuation
Overall 23 (17.5) 12 (7.1
Diarrhea 10 (7.6) 4 (2.4
Headache 7 (5.3) 1 (0.6
Nausea/vomiting 3 (2.3) 2 (1.2
Depression 1 (0.7)
UC relapse 1 (0.7)
Anemia 1 (0.7)
AE, Adverse events; csDMARD, conventional synthetic disease-modif
Assessment of Clinical Efficacy; PsA, psoriatic arthritis; RAPPER, R
RCT, randomized controlled trial; SD, standard deviation; UC, ulcerative c
*P value versus PALACE I.
J AM ACAD DERMATOLTo confirm these findings in patients with PsA, we
performed a retrospective analysis of data from
the Real-Life Apremilast for Psoriatic Arthritis
Evaluation Registry (RAPPER), which is a multi-
centric observational cohort of patients with PsA
(the compilation of which has been approved by
local ethics committees) that includes all patients
with PsA who are at least 18 years of age and have
been treated with apremilast in 12 Italian tertiary
rheumatology centers. Treatments were adminis-
tered according to the licensed regimen, and
concomitant therapies were prescribed if ordered
by the referring rheumatologist. Reported AEs and
tolerability (AEs leading to discontinuation) were
assessed over a 6-month follow-up period.
Withdrawals were considered definitive when
indicated in the registry or when no consecutive
reintroduction of treatment was reported. A
chi-square test was used to compare safety outcomesmilast population included in RCTs and in the
Cohort
I1
)
PALACE II2
(N = 162)
PALACE III3
(N = 167)
Pooled RCTs
(N = 497)
P value vs
pooled
.8) 95 (58.6) 88 (53) 275 (55.3) .11
.7) 50.5 (11.2) 49.9 (11.4) 50.6 (11.4)
) 6.8 (7.6) 7.5 (7.6) 7.5 (7.7)
.6) 82.7 (18.9) 83.7 (20.1) 84.5 (19.5)
) 29.2 (6.2) 29.2 (6.4) 29.6 (6.2)
.4) 23 (14.2) 43 (26) 107 (21.5) \.0001
.1) 113 (69.8) 101 (61) 320 (64.3) \.0001
) 24 (14.8) 26 (16) 82 (16.4) .68
.7) 19 (11.7) 20 (12) 57 (11.4) .53
.5) 26 (16.0) 31 (19) 88 (17.7) .004
) 11 (6.8) 12 (7) 30 (6) .67
) 12 (7.4) 12 (7) 36 (7.2) .001
) .05*
) .023*
) .65*
ying antirheumatic drug; PALACE, Psoriatic Arthritis Long-term
eal-Life Apremilast for Psoriatic Arthritis Evaluation Registry;
olitis.
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e120 Notes & Commentsbetween the RAPPER cohort and the pooled
population from the PALACE I, II, and III clinical
trials. P values of .05 or lower were considered
statistically significant.
The study population of the RAPPER cohort
included 131 patients with long-standing PsA
(mean disease duration, 10.8 years) presenting with
oligoarticular (58%), entheseal (26.7%), polyarticular
(22%), axial (12.2%), skin (48%), and nail (40.4%)
involvement. About two-thirds of patients (64.1%)
had at least 1 comorbidity, in particular, a history of
malignancies (25.9%) and a positive screening result
for latent tuberculosis (16.3%).
Diarrhea (14.5%), headache (9.1%), and nausea/
vomiting (7.6%) were the most commonly reported
AEs (Table I). We observed no cases of malignancy,
opportunistic infection, or tuberculosis reactivation.
Apremilast withdrawal because of AEs was reported
in 23 patients after a mean period of 82.3 plus or
minus 47.4 days. The most frequent AEs leading
to discontinuation were diarrhea (n ¼ 10),
nausea/vomiting (n ¼ 3), and headache (n ¼ 7).
No difference in the incidence of AEs between the
RAPPER and PALACE pooled populations was
found, the only exception being the incidence of
nausea/vomiting (17.7% [P ¼ .004]); however, the
rate of discontinuation due to AEs was significantly
higher in the RAPPER cohort (P¼ .001). On the basis
of the available data, withdrawals because of
diarrhea (P ¼ .05) and headache (P ¼ .023) were
each more common in our experience than in the
PALACE I study. These findings can be partially
explained by the differences in population
characteristics between RAPPER and PALACE
cohorts, in particular, regarding the proportions of
enrolled patients with failure of biologics (47.7%
versus 21.5%, respectively [P \ .0001]) and the
inclusion in the RAPPER cohort of patients carrying
comorbidities excluded by the PALACE enrollment
criteria.
In conclusion,ourdata confirmed the lower real-life
tolerability of apremilast in a cohort of patients with
PsA than in the randomized controlled trials previously
reportedby Ighani et al4 in patientswith psoriasis,with
gastrointestinal complaints and headache as the most
frequent reasons for drug discontinuation.
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